Navigation Links
Adamis Pharmaceuticals CEO Provides Update for Shareholders
Date:5/3/2013

ur Beclomethasone-HFA product to initiate Phase III studies in asthma and COPD
  • Finalizing our allergic rhinitis product development in order to initiate Phase III clinical trials
  • Acquiring or in-licensing an established product or technology that, following regulatory marketing approvals, will compete in large (multi-billion dollar) product markets and will be synergistic with our existing assets.
  • On the Biotech side, we are focused on:

    • Completing our Phase I prostate cancer drug trial
    • Finalizing the activities necessary to begin a Phase I/II trial for our second prostate compound
    • Initiating a Phase II prostate cancer vaccine trial for TeloB-VAX.

    If we are able to complete additional financing transactions and make progress on our objectives, we intend to take the necessary steps to be in a position to list our common stock on a national stock exchange such as the NYSE-Amex or NASDAQ.  An up-listing could lead to an increase in shareholder value, give Adamis more market exposure, increase liquidity and partnering activities and increase our shareholder base to include more fundamental health care investors.

    I would like to thank all of our shareholders for their continued support and patience.  We will all do our very best to make Adamis a company that you will all be very proud of owning.

    Best regards,

    Dennis J. Carlo , Ph.D
    President and CEO

    About Adamis Pharmaceuticals Corporation

    Adamis Pharmaceuticals Corporation is a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology.  Products in its specialty pharmaceutical pipeline include the Epinephrine Injection PFS syringe for use in the emergency treatment of a
    '/>"/>

    SOURCE Adamis Pharmaceuticals Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
    2. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
    3. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
    4. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
    5. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
    6. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
    7. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
    8. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
    9. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
    10. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
    11. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/1/2015)... ... September 01, 2015 , ... A ... discovered by researchers at the Keck Graduate Institute and its collaborators. The discovery ... The findings were published online on August 27 by Scientific Reports, an open ...
    (Date:8/31/2015)... ... 31, 2015 , ... The Global Supply Chain Resiliency Council ... resiliency practitioners with luminaries and thought leaders to advance the professional discipline through ... innovations and performance excellence. At that time its principle sponsor, Resilinc , ...
    (Date:8/31/2015)... Aug. 31, 2015 Research and Markets ( ... "Argentina Biomedical Sensors Market - Growth, Trends & Forecasts ... The Argentina Biomedical Sensors market is estimated at $0.17 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
    (Date:8/31/2015)... people with Down syndrome, news from Elixirgen, LLC ... in the Science + Technology Park at Johns Hopkins, ... for people with Down syndrome and other chromosome disorders in ... Edwards syndrome aneuploidies in human cell cultures, " published ... to develop this technology into a treatment for the ...
    Breaking Biology Technology:Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2New Down syndrome therapy discovered 2
    ... ground-breaking treatment option for victims of whiplash associated disorders (WAD). ... Z Therapy is the first and only rehabilitation specialist in North ... neck pain. , ... Dallas, TX (PRWEB) April 21, ...
    ... NxStage Medical, Inc. (Nasdaq: NXTM ), a ... to release its financial results for the first quarter ... before the opening of the financial markets.NxStage will also ... on Friday, May 8, 2009 to discuss its first ...
    ... LLC announced today that it has issued an Executive ... 56-page report can be found at www.crystalra.com ... is a closely held pharmaceutical company focused exclusively on ... a technology spinout from Bayer HealthCare LLC, ACT Biotech ...
    Cached Biology Technology:Z Therapy Is The First In North Texas To Offer Revolutionary Treatment Option For Neck Pain Sufferers 2NxStage to Report First Quarter 2009 Financial Results 2Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc. 2Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc. 3
    (Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
    (Date:7/31/2015)... Chine, 31 juillet 2015 La 10e ... ) sera organisée par le BGI du 22 ... en Chine. La conférence ... inauguration en 2006, l,ICG est devenue l,une des ... domaine des « omiques » et c,est aussi la plus ...
    (Date:7/31/2015)... 31. Juli 2015 Die 10. internationale Konferenz zu ... veranstaltet und findet vom 22. bis 25. Oktober ... statt. Die Konferenz feiert in ... 2006 ist die ICG weltweit zu einem der ... ist eines der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen ...
    Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3
    ... the most abundant biomass material on Earth, and therefore ... for the production of advance biofuels. A major roadblock, ... Researchers with the U.S. Department of Energy (DOE),s Joint ... removing this roadblock by identifying a gene in rice ...
    ... experts from around the world in Clinical Rehabilitation, Applied ... to 16th, at the First International Conference on NeuroRehabilitation ... conference, organized in Toledo (Spain) by researchers of the ... state of the therapies that are currently being conducted ...
    ... 2012) John Wiley & Sons, Inc., (NYSE:JWa, JWb), ... areas of scientific, technical, medical, and scholarly research; professional ... TED, the non-profit devoted to Ideas Worth Spreading, to ... series of "TED Studies." To support the ...
    Cached Biology News:A better route to xylan 2A better route to xylan 3Leader experts in neurorehabilitation gather in Toledo, Spain 2Wiley Partners with TED 2
    ... Peptide sequences: Two separate vials ... to the same sequence used as ... (Catalog No. 160890) ... Cayman's guanylate cyclase polyclonal antiserum (Catalog ...
    ... 3B8A10. Immunogen: Recombinant ... C-terminal region of human ... for the human ubiquilin ... (positive control: 293 cells). ...
    ... PinPoint™ Vector Sequencing Primer is designed for ... Vectors (Cat.# V2031, V2051, V2061). The primer ... at nucleotides 325343, approximately 4050 base pairs ... can be used to determine if an ...
    ... The versatile Zymo-Spin I-96 Plate can be ... manifolds for the large-scale (i.e., 96-well) purification ... polypropylene construction and unique silica-based matrix make ... g DNA or RNA in = 10 ...
    Biology Products: